David R. Jones, MD - Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer

Chia sẻ

Manage episode 280043383 series 103624
Thông tin tác giả PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education được phát hiện bởi Player FM và cộng đồng của chúng tôi - bản quyền thuộc sở hữu của nhà sản xuất (publisher), không thuộc về Player FM, và audio được phát trực tiếp từ máy chủ của họ. Bạn chỉ cần nhấn nút Theo dõi (Subscribe) để nhận thông tin cập nhật từ Player FM, hoặc dán URL feed vào các ứng dụng podcast khác.
Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon’s role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

284 tập